Infections

FDA Expands Authorization Around Remdesivir to Treat COVID-19

On January 21, the FDA expanded the use of remdesivir to non-hospitalized adults and children who have mild-to-moderate COVID-19, who are at risk of severe disease. Previously, remdesivir was only available to hospitalized patients. This decision was based on a clinical trial including 562 participants with mild-to-moderate COVID-19, who had displayed symptoms within the previous 7 days and had at least one risk factor for severe disease.

Read More »

Covid-19 Outcomes in Autoimmune Disease Patients

Autoimmune disease is currently considered a risk factor for severe COVID-19. A research article published in Rheumatology last Fall summarized 30-day outcomes of autoimmune disease (AD) patients following hospitalization with COVID-19. AD patients diagnosed and/or hospitalized between January and June 2020 with COVID-19 were included, and their 30 day outcomes were compared to patients with at least one AD hospitalized with influenza from September 2017 through April 2018.

Read More »

Hybrid Immunity in Autoimmune Rheumatic Disease Patients

Researchers at the Center For Arthritis and Rheumatism Excellence in Kerala, India, tested immune responses in autoimmune rheumatic disease patients (AIRD) after one dose of a COVID-19 vaccine following a SARS-CoV-2 infection versus two doses of a COVID-19 vaccine without a previous infection. 

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.